

## References

I-38

1. Rituxan® (rituximab) package insert, Genentech, Inc., San Francisco, CA, Revised 01/2008, 10/2012, 09/2013, 08/2014.
2. Wang K, Jiang Y, Zheng W, et al. Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in b-cell lymphoma. *PLoS One*. 2013;8(2):e56829.
3. Wang M, Fowler N, Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. *Leukemia*. 2013;27(9):1902-9.
4. Ohmachi K, Niitsu N, Uchida T, et al. Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Journal of Clinical Oncology*. 2013;31(17):2103-2109.
5. Mok C. Rituximab for the treatment of rheumatoid arthritis: An update. *Drug Design, Development and Therapy*. 2014;8: 87–100.
6. Darwish M, Burke J, Hellriegel E, et al. An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma. *Cancer Chemotherapy and Pharmacology*. 2014;73:1119–1127.
7. Harb D, Moukadem H, Nayfe R, et al. The off-label use of rituximab for the management of inflammatory disorders: American University of Beirut Medical Center experience. *Archive of Rheumatology*. 2014;29(3):194-202.
8. Mealy M, Levy M. Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab. *Journal of Neuroimmunology*. 2015;287:29–30.
9. Torres J, Pruitt A, Balcer L, et al. Analysis of the treatment of neuromyelitis optica. *Journal of the Neurological Sciences*. 2015;351(1–2):31–35.
10. Smolen J, Landewé, Breedveld F, et al. European League Against Rheumatism’s (EULAR) recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Annals of the Rheumatic Diseases*. 2014;73(3):492-509.
11. Hui-Yuen JS, Nguyen SC, Asknase AD. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus. *Lupus*. 2016;25:1086–1096.
12. Memon AB, Javed A, Caon C, et al. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. *PLoS ONE*. 2018;13(1): e0190425.
13. MICROMEDEX®SOLUTIONS Compendia. 2018. Rituximab.
14. MICROMEDEX®SOLUTIONS Compendia. 2018. Rituximab/Hyaluronidase Human, Recombinant.
15. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Rituximab; Hyaluronidase.

16. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Rituximab.
17. NCCN Drugs & Biologics Compendium™. Rituximab. 2018. National Comprehensive Cancer Network (NCCN).
18. NCCN Drugs & Biologics Compendium™. Rituximab and hyaluronidase human. 2018. National Comprehensive Cancer Network (NCCN).
19. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care and Research* 2012;64(6):797-808.
20. Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. *J Am Soc Nephrol*. 2012;23(8):1416-1425.
21. Bomback AS, Derebail VK, McGregor JG, et al. Rituximab therapy for membranous nephropathy: a systematic review. *Clin J Am Soc Nephrol*. 2009;4:734-744.
22. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. *Transplantation*. 2010;89(9):1095-1102.
23. Jordan S, Distler JHW, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. *Annals of the Rheumatic Diseases*. Published Online First: 17 January 2014. doi: 10.1136/annrheumdis-2013-204522.
24. Schmidt, E. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. *BJD*. 2007; 156(2):352-356.
25. Thiel J, et al. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). *Arthritis Research & Therapy*. 2013;15:R133.
26. Lorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. *J Neurol*. 2015; 262(5):1115-1119.
27. Harambat J, Lamireau D, Delmas Y, et al. Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review. *Pediatr Crit Care Med*. 2011; 12(2):e90-e93.
28. Wiestner A, Cho HJ, Asch AS, et al. Rituximab in the treatment of acquired factor VIII inhibitors. *Blood*. 2002; 100(9):3426-3428.
29. Mavragani CP, Moutsopoulos. Conventional therapy of Sjögren's Syndrome. *Clin Rev Allerg Immunol*. 2007; 32:284-291.